What is Lokelma (sodium zirconium cyclosilicate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Lokelma?

Lokelma (sodium zirconium cyclosilicate, or SZC) is a non-absorbed oral potassium binder that rapidly lowers serum potassium by selectively exchanging potassium for hydrogen and sodium in the gastrointestinal tract, approved for treating hyperkalemia in adults. 1

Mechanism of Action

Lokelma is a zirconium silicate compound with a crystalline structure that preferentially captures potassium ions in the GI lumen, even in the presence of other cations like calcium and magnesium 1. The drug:

  • Exchanges potassium for hydrogen and sodium as it passes through the colon
  • Increases fecal potassium excretion by binding potassium in the intestinal lumen
  • Is not systemically absorbed—it works entirely within the GI tract and is eliminated in feces 1
  • Contains 400 mg of sodium per 5 g dose, which clinicians must account for in patients requiring sodium restriction 1

Clinical Efficacy Profile

Acute Hyperkalemia Management

SZC demonstrates the fastest onset of action among available potassium binders, with measurable reductions in serum potassium within 1 hour of administration 2. In emergency department patients with severe hyperkalemia (≥5.8 mEq/L), three 10-g doses within 10 hours reduced mean serum potassium by 0.72 mEq/L within 2 hours when added to insulin plus glucose 2.

Chronic Hyperkalemia Management

For sustained control 2:

  • Three-times-daily dosing (10 g TID) significantly reduces serum potassium within 48 hours
  • Once-daily maintenance dosing (5 or 10 g) effectively maintains normokalemia for 14-28 days
  • Long-term efficacy documented up to 12 months in clinical trials
  • In the DIALIZE study, once-daily SZC on non-dialysis days maintained normal pre-dialysis potassium levels over 8 weeks in ESRD patients 2

Safety Profile

SZC has not been associated with serious adverse events in randomized trials 2. The most common adverse effects are:

Primary Concerns

  • Hypokalemia (4.1% developed serum potassium <3.5 mEq/L, resolved with dose adjustment) 1
  • Edema (dose-dependent: 4.4% at 5 g, 5.9% at 10 g, 16.1% at 15 g daily vs 2.4% placebo) 2, 1

Additional Metabolic Effects

  • Increases serum bicarbonate in a dose-dependent manner (1.1-2.6 mmol/L), which may benefit patients with metabolic acidosis 2
  • Unlike patiromer, does not cause hypercalcemia or hypomagnesemia 2

Drug Interactions

SZC transiently increases gastric pH, which can alter absorption of pH-dependent medications 1. Key management points:

  • Separate other oral medications by at least 2 hours before or after SZC administration
  • Medications with increased exposure when co-administered: furosemide, atorvastatin (weak acids)
  • Medications with decreased exposure: dabigatran (weak bases)
  • No interaction documented with: losartan, glipizide, levothyroxine, digoxin, apixaban, metformin, spironolactone, and others 1

Clinical Context and Guideline Support

SZC represents a paradigm shift in hyperkalemia management by enabling continuation of life-saving RAAS inhibitor therapy 2, 3. The 2021 Mayo Clinic guidelines emphasize that newer potassium binders like SZC should be considered in patients with chronic hyperkalemia despite optimized diuretic therapy, rather than discontinuing or reducing RAAS inhibitors 2.

Advantages Over Older Agents

  • More palatable than sodium polystyrene sulfonate (SPS), facilitating adherence 2
  • Faster onset than patiromer (1 hour vs 7 hours) 2
  • More selective for potassium binding 2
  • Does not require separation from food, unlike patiromer which must be taken 3 hours apart from other medications 2

Special Populations

  • Pregnancy/Lactation: No systemic absorption means no fetal or infant exposure expected 1
  • Geriatric: No dose adjustment needed; 58% of trial participants were ≥65 years 1
  • Pediatric: Safety and effectiveness not established 1
  • Dialysis patients: Effective when given on non-dialysis days for maintaining pre-dialysis potassium control 2

Important Clinical Caveats

Monitor for edema development, particularly at higher doses (≥10 g daily), as this may limit use in volume-sensitive patients with heart failure or advanced CKD 2, 1. The sodium content (400 mg per 5 g dose) must be factored into total sodium intake for patients on sodium restriction 1.

Radiologic consideration: SZC appears hyperattenuating on CT imaging due to zirconium content and can be mistaken for GI bleeding or oral contrast 4. Inform radiology teams when patients are taking this medication.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.